Fifth Amendment to Exclusive Distribution Agreement dated July 29, 2024 by and between Revance Therapeutics, Inc. and Teoxane SA

dated July 29th, 2024

by and among

Rue de Lyon 105, CH-1203 Geneva, Switzerland

and

7555 Gateway Boulevard Newark, California, USA

(the Supplier and the Distributor, together the Parties, and each a Party)

A.On January 10, 2020, the Parties entered into an Exclusive Distribution Agreement (the Original Exclusive Distribution Agreement) to distribute certain products in the Territory.

D.On December 16, 2022, the parties entered into a Third Amendment Agreement to update the Annex 6.3 — Quality Agreement and replace it by the Annex 6.3 — First Restated and Amended Quality Agreement (The Third Amendment Agreement).

E.On June 13, 2024, the parties entered into a Fourth Amendment Agreement to update the Annex 6.3 — Quality Agreement and replace it by the Annex 6.3 — Second Restated and Amended Quality Agreement (The Fourth Amendment Agreement).

G.The parties wish to amend the "Cure" period in Section 16.2(a)(i) (Termination for Breach) from ninety (90) days to sixty (60) days.

H.The purpose of this Fifth Amendment Agreement is to formally amend the Exclusive Distribution Agreement in accordance with its Clause 19.7 in order to reflect the Parties new agreements regarding the above.

Clause 16.2(a)(i) of the Exclusive Distribution Agreement is deleted in its entirety and is replaced by the following new Clause 16.2(a) as follows:

(a) Without prejudice to any other rights or remedies provided under this Agreement, either Party has the right, but not the obligation, to terminate this Agreement immediately upon written notice served to the other Party in writing if the other Party (the Breaching Party) has materially breached its obligations under this Agreement, and the Breaching Party has not cured such material breach within (i) sixty (60) calendar days of receipt of a written notice of such breach by the nonbreaching Party to remedy such breach or (ii) in the case of any

nonpayment due under this Agreement, thirty (30) calendar days of receipt of a written notice requesting payment of such due amount.

Other than as set for in this Fifth Amendment Agreement, the Exclusive Distribution Agreement and its Annexes shall not be amended, changed, modified or varied in any way, and each Party retains its rights and obligations under the Exclusive Distribution Agreement in its version prior to the Amendment Effective Date up until the Amendment Effective Date.

The amendments set forth in this Fifth Amendment Agreement shall be effective as of July 29, 2024 ("Amendment Effective Date").

This Fifth Amendment Agreement and the Exclusive Distribution Agreement including its Annexes, taken together, shall constitute one and the same agreement for all purposes to be designated as the Exclusive Distribution Agreement.

Each Party shall bear its own taxes, costs and expenses related to the preparation, execution and performance of this Fifth Amendment Agreement.

This Fifth Amendment Agreement may be executed in one or more counterparts each of which will be deemed to be an original copy of this Fifth Amendment Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement, including counterparts transmitted via facsimile or by PDF file (portable document format file).